{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-016250","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.769533+00:00","generated_at":"2026-06-16T05:05:18.406688+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ovid Therapeutics enters ROCK2 inhibitor collaboration with Graviton; invests $10M for exclusive CNS rights","bullets":["Ovid pays $10M upfront in Graviton Series A preferred stock for exclusive license to GV101 and other ROCK2 inhibitors.","Royalties on net sales range from mid-teens to high-teens; no milestone payments are required.","Initial focus: cerebral cavernous malformations and seizure disorders; GV101 is in Phase 1.","Graviton conducts development through Phase 2; Ovid handles post-Phase 2 development and commercialization worldwide except China, Hong Kong, Macau, Taiwan.","Ovid CEO Dr. Jeremy Levin will join Graviton's Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-016250","json":"https://secwatch.observer/filing/0000950170-23-016250.json","markdown":"https://secwatch.observer/filing/0000950170-23-016250.md","text":"https://secwatch.observer/filing/0000950170-23-016250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000095017023016250/0000950170-23-016250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000095017023016250/ovid-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:05:18.406688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}